We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Soon after health authorities administered an NIH-developed antibody to Ebola patients in the Democratic Republic of Congo, the country’s health ministry has approved another four experimental treatments to help contain the outbreak.